NeoGenomics Company Profile (NASDAQ:NEO)

About NeoGenomics (NASDAQ:NEO)

NeoGenomics logoNeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical & Diagnostic Laboratories
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NEO
  • CUSIP: N/A
  • Web: www.neogenomics.com
Capitalization:
  • Market Cap: $734.34 million
  • Outstanding Shares: 79,388,000
Average Prices:
  • 50 Day Moving Avg: $9.20
  • 200 Day Moving Avg: $8.26
  • 52 Week Range: $6.90 - $9.93
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 48.21
  • P/E Growth: 2.57
Sales & Book Value:
  • Annual Revenue: $249.02 million
  • Price / Sales: 2.92
  • Book Value: $2.13 per share
  • Price / Book: 4.30
Profitability:
  • EBIDTA: $26.72 million
  • Net Margins: -2.81%
  • Return on Equity: 6.09%
  • Return on Assets: 3.11%
Debt:
  • Debt-to-Equity Ratio: 0.60%
  • Current Ratio: 2.37%
  • Quick Ratio: 2.21%
Misc:
  • Average Volume: 304,189 shs.
  • Beta: 1.05
  • Short Ratio: 24.79
 

Frequently Asked Questions for NeoGenomics (NASDAQ:NEO)

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its earnings results on Tuesday, July, 25th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. The business had revenue of $66.09 million for the quarter, compared to analyst estimates of $62.95 million. NeoGenomics had a positive return on equity of 6.09% and a negative net margin of 2.81%. The business's quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the company posted $0.04 EPS. View NeoGenomics' Earnings History.

When will NeoGenomics make its next earnings announcement?

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for NeoGenomics.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share guidance of $0.17-0.21 for the period, compared to the Thomson Reuters consensus estimate of $0.18. The company issued revenue guidance of $255-265 million, compared to the consensus revenue estimate of $258.23 million.

Where is NeoGenomics' stock going? Where will NeoGenomics' stock price be in 2017?

5 brokerages have issued twelve-month price targets for NeoGenomics' stock. Their forecasts range from $10.00 to $11.00. On average, they anticipate NeoGenomics' stock price to reach $10.75 in the next year. View Analyst Ratings for NeoGenomics.

What are analysts saying about NeoGenomics stock?

Here are some recent quotes from research analysts about NeoGenomics stock:

  • 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (7/29/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $11 price target following last week's meeting with management. The company highlighted the strategic benefits of its tech-only offering, the Clarient acquisition, positive secular trends that are driving cancer diagnostics, and NEO's strong management team. The biggest takeaway, in our view, was that the Clarient integration continues to progress, which should drive further cost synergies as well as revenue synergies. We estimate that there is a $10-16M low-hanging revenue opportunity from targeting 100 Clarient accounts. We believe that the company will be able to unlock 25-40% of these and, thus, we are modeling $4-6M of revenue synergies ($2-3M in EBITDA contribution), with significant potential upside." (3/22/2017)

Who are some of NeoGenomics' key competitors?

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:

  • Douglas M. VanOort, Chairman of the Board, Chief Executive Officer
  • George A. Cardoza, Chief Financial Officer
  • Robert J. Shovlin, Chief Operating Officer
  • Steven C. Jones, Executive Vice President - Finance, Chief Compliance Officer, Director
  • Edwin F. Weidig III, CPA, Principal Accounting Officer, Vice President - Finance
  • Steven A. Ross, Chief Information Officer
  • Steven G. Brodie Ph.d., Vice President - Operations
  • Jennifer Balliet, Vice President - Human Resources
  • Sally Agersborg M.D. Ph.D., Director of Hematopathology and Medical Director
  • Maher Albitar M.D., Chief Medical Officer, Director - Research and Development

Who owns NeoGenomics stock?

NeoGenomics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include General Electric Co. (18.93%), Vanguard Group Inc. (3.44%), First Light Asset Management LLC (3.37%), Artisan Partners Limited Partnership (2.98%), Janus Henderson Group PLC (2.90%) and Russell Investments Group Ltd. (2.52%). Company insiders that own NeoGenomics stock include Alison L Hannah, Bruce K Crowther, George Cardoza, Jennifer Balliet, Lynn A Tetrault, Maher Albitar, Oort Douglas M Van, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.

Who sold NeoGenomics stock? Who is selling NeoGenomics stock?

NeoGenomics' stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Uniplan Investment Counsel Inc., Wells Fargo & Company MN, Icon Advisers Inc. Co., Artisan Partners Limited Partnership, Kopp Investment Advisors LLC, Emerald Advisers Inc. PA and Swiss National Bank. Company insiders that have sold NeoGenomics stock in the last year include Jennifer Balliet, Maher Albitar, Steven A Ross and Steven G Brodie. View Insider Buying and Selling for NeoGenomics.

Who bought NeoGenomics stock? Who is buying NeoGenomics stock?

NeoGenomics' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Falcon Point Capital LLC, Russell Investments Group Ltd., Granite Investment Partners LLC, Northpointe Capital LLC, Royce & Associates LP, Strs Ohio and Rice Hall James & Associates LLC. Company insiders that have bought NeoGenomics stock in the last two years include Alison L Hannah, Bruce K Crowther, Lynn A Tetrault and Robert J Shovlin. View Insider Buying and Selling for NeoGenomics.

How do I buy NeoGenomics stock?

Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NeoGenomics stock can currently be purchased for approximately $9.16.


MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NeoGenomics (NASDAQ:NEO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $10.75 (17.36% upside)

Analysts' Ratings History for NeoGenomics (NASDAQ:NEO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/28/2017BTIG ResearchReiterated RatingBuy$11.00LowView Rating Details
5/27/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/AView Rating Details
11/16/2016Axiom SecuritiesReiterated RatingHold -> SellN/AView Rating Details
10/3/2016First AnalysisInitiated CoverageOverweight$11.00N/AView Rating Details
9/8/2016Raymond James Financial, Inc.Initiated CoverageOutperform$10.00N/AView Rating Details
7/27/2016Benchmark Co.Boost Price TargetBuy$10.00 -> $12.00N/AView Rating Details
7/9/2016Craig HallumReiterated RatingBuyN/AView Rating Details
5/11/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
1/7/2016Janney Montgomery ScottInitiated CoverageBuy$11.00N/AView Rating Details
10/26/2015William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 8/19/2015 forward)

Earnings

Earnings History for NeoGenomics (NASDAQ:NEO)
Earnings by Quarter for NeoGenomics (NASDAQ:NEO)
Earnings History by Quarter for NeoGenomics (NASDAQ NEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$0.05N/AView Earnings Details
7/25/2017Q2 2017$0.01$0.04$62.95 million$66.09 millionViewN/AView Earnings Details
4/26/2017Q1 2017$0.01$0.03$61.26 million$61.68 millionViewN/AView Earnings Details
2/22/2017Q416$0.03$0.05$61.83 million$60.50 millionViewListenView Earnings Details
10/26/2016Q316$0.03$0.04$61.00 million$60.76 millionViewListenView Earnings Details
7/26/2016Q216$0.03$0.04$61.07 million$63.10 millionViewListenView Earnings Details
4/27/2016Q116($0.07)$0.03$57.00 million$59.70 millionViewListenView Earnings Details
3/1/2016Q415$0.02($0.03)$26.46 million$27.30 millionViewN/AView Earnings Details
4/28/2015Q115($0.02)($0.01)$23.36 million$23.00 millionViewN/AView Earnings Details
2/24/2015Q414$0.01$0.02$24.30 million$25.00 millionViewN/AView Earnings Details
10/30/2014Q314($0.01)$0.01$22.43 million$23.20 millionViewN/AView Earnings Details
7/17/2014Q214$0.01$0.01$19.84 million$20.70 millionViewN/AView Earnings Details
2/19/2014Q413$0.02$0.04$17.80 million$18.30 millionViewN/AView Earnings Details
10/23/2013Q313$0.01$0.02$16.84 million$16.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.01$16.20 million$15.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NeoGenomics (NASDAQ:NEO)
Current Year EPS Consensus Estimate: $0.11 EPS
Next Year EPS Consensus Estimate: $0.19 EPS

Dividends

Dividend History for NeoGenomics (NASDAQ:NEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NeoGenomics (NASDAQ:NEO)
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 82.56%
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/27/2017Alison L HannahDirectorBuy20,000$9.19$183,800.00View SEC Filing  
6/22/2017Jennifer BallietVPSell10,723$8.49$91,038.27View SEC Filing  
6/5/2017Steven A RossInsiderSell70,833$7.76$549,664.08View SEC Filing  
5/26/2017Jennifer BallietVPSell3,334$7.50$25,005.00View SEC Filing  
3/20/2017Steven G BrodieInsiderSell50,000$7.93$396,500.00View SEC Filing  
9/23/2016Maher AlbitarInsiderSell2,800$8.40$23,520.00View SEC Filing  
9/20/2016Maher AlbitarInsiderSell105,300$8.20$863,460.00View SEC Filing  
9/12/2016Maher AlbitarInsiderSell60,075$8.23$494,417.25View SEC Filing  
8/19/2016Maher AlbitarInsiderSell370,000$8.23$3,045,100.00View SEC Filing  
5/27/2016Oort Douglas M VanCEOSell481,387$8.73$4,202,508.51View SEC Filing  
5/18/2016Steven A RossInsiderSell18,000$8.50$153,000.00View SEC Filing  
5/9/2016Steven A RossInsiderSell15,000$8.22$123,300.00View SEC Filing  
5/2/2016Steven C JonesVPSell177,745$8.21$1,459,286.45View SEC Filing  
4/29/2016Steven A RossInsiderSell112,500$8.11$912,375.00View SEC Filing  
3/11/2016George CardozaCFOSell32,000$6.83$218,560.00View SEC Filing  
3/9/2016Oort Douglas M VanCEOSell450,000$7.10$3,195,000.00View SEC Filing  
3/3/2016Alison L HannahDirectorBuy10,000$6.90$69,000.00View SEC Filing  
12/7/2015Lynn A TetraultDirectorBuy3,500$7.72$27,020.00View SEC Filing  
12/3/2015Robert J ShovlinCOOBuy6,550$7.75$50,762.50View SEC Filing  
11/27/2015Steven C JonesVPSell385,000$8.09$3,114,650.00View SEC Filing  
11/2/2015Bruce K CrowtherDirectorBuy6,400$7.81$49,984.00View SEC Filing  
12/19/2014Robert H HorelVPSell32,389$4.21$136,357.69View SEC Filing  
12/18/2014Robert H HorelVPSell62,893$4.20$264,150.60View SEC Filing  
12/4/2014Michael T DentDirectorSell11,800$4.50$53,100.00View SEC Filing  
11/26/2014George CardozaCFOSell60,000$4.28$256,800.00View SEC Filing  
11/21/2014Michael T DentDirectorSell33,200$4.51$149,732.00View SEC Filing  
5/22/2014Robert P GaspariniInsiderSell100,000$3.49$349,000.00View SEC Filing  
5/19/2014Robert GaspariniInsiderSell10,000$3.65$36,500.00View SEC Filing  
3/28/2014Maher AlbitarInsiderBuy14,492$3.51$50,866.92View SEC Filing  
3/5/2014Michael T DentDirectorSell300,000$3.00$900,000.00View SEC Filing  
12/11/2013Robert P GaspariniInsiderSell20,100$3.70$74,370.00View SEC Filing  
12/9/2013George CardozaCFOSell20,000$3.66$73,200.00View SEC Filing  
12/5/2013Robert P GaspariniInsiderSell32,996$3.67$121,095.32View SEC Filing  
12/3/2013Robert P GaspariniInsiderSell32,146$3.67$117,975.82View SEC Filing  
11/25/2013Steven C JonesVPSell112,969$3.58$404,429.02View SEC Filing  
4/30/2013Steven C JonesDirectorSell100,000$3.71$371,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for NeoGenomics (NASDAQ:NEO)
Latest Headlines for NeoGenomics (NASDAQ:NEO)
Source:
DateHeadline
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Upgraded at ValuEngine
www.americanbankingnews.com - August 7 at 11:14 PM
americanbankingnews.com logoNeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 5 at 12:40 AM
americanbankingnews.com logoFinancial Review: NeoGenomics (NEO) & RadNet (RDNT)
www.americanbankingnews.com - August 4 at 12:18 AM
americanbankingnews.com logo$0.03 EPS Expected for NeoGenomics, Inc. (NASDAQ:NEO) This Quarter
www.americanbankingnews.com - August 1 at 10:26 PM
americanbankingnews.com logoHead to Head Review: NeoGenomics (NASDAQ:NEO) versus RadNet (RDNT)
www.americanbankingnews.com - August 1 at 4:32 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Director Alison L. Hannah Purchases 20,000 Shares
www.americanbankingnews.com - July 31 at 7:44 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - July 29 at 2:19 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 29 at 9:04 AM
americanbankingnews.com logoRadNet (RDNT) vs. NeoGenomics (NEO) Head to Head Contrast
www.americanbankingnews.com - July 28 at 2:31 PM
finance.yahoo.com logoEdited Transcript of NEO earnings conference call or presentation 25-Jul-17 2:00pm GMT
finance.yahoo.com - July 28 at 6:04 AM
reuters.com logoBRIEF-Neogenomics Inc Q2 revenue $66.1 million
www.reuters.com - July 26 at 4:00 AM
finance.yahoo.com logoNeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017
finance.yahoo.com - July 26 at 4:00 AM
finance.yahoo.com logoInvestor Network: NeoGenomics, Inc. to Host Earnings Call
finance.yahoo.com - July 26 at 4:00 AM
finance.yahoo.com logoNeoGenomics reports 2Q loss
finance.yahoo.com - July 26 at 4:00 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - July 25 at 10:08 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Updates FY17 Earnings Guidance
www.americanbankingnews.com - July 25 at 10:08 AM
finance.yahoo.com logoInvestor Network Invites You to the NeoGenomics Second Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, July 25, 2017
finance.yahoo.com - July 25 at 6:04 AM
americanbankingnews.com logoContrasting RadNet (RDNT) and NeoGenomics (NASDAQ:NEO)
www.americanbankingnews.com - July 15 at 7:46 AM
americanbankingnews.com logo Analysts Expect NeoGenomics, Inc. (NASDAQ:NEO) Will Announce Quarterly Sales of $63.06 Million
www.americanbankingnews.com - July 12 at 10:32 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 11 at 12:40 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Expected to Announce Earnings of $0.01 Per Share
www.americanbankingnews.com - July 10 at 4:26 PM
streetinsider.com logoForm 4 NEOGENOMICS INC For: Jul 05 Filed by: BRODIE STEVEN G.
www.streetinsider.com - July 7 at 1:46 AM
finance.yahoo.com logoETFs with exposure to NeoGenomics, Inc. : July 3, 2017
finance.yahoo.com - July 4 at 12:23 AM
finance.yahoo.com logoNeoGenomics Schedules its Q2 2017 Earnings Release for July 25, 2017
finance.yahoo.com - June 28 at 11:39 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - June 27 at 7:24 AM
americanbankingnews.com logoJennifer Balliet Sells 10,723 Shares of NeoGenomics, Inc. (NEO) Stock
www.americanbankingnews.com - June 26 at 7:38 PM
americanbankingnews.com logoContrasting NeoGenomics (NEO) and Enzo Biochem (ENZ)
www.americanbankingnews.com - June 26 at 8:16 AM
prnewswire.com logoFDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies
www.prnewswire.com - June 24 at 5:24 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - June 24 at 12:06 AM
finance.yahoo.com logoETFs with exposure to NeoGenomics, Inc. : June 22, 2017
finance.yahoo.com - June 23 at 8:22 AM
americanbankingnews.com logo$63.13 Million in Sales Expected for NeoGenomics, Inc. (NEO) This Quarter
www.americanbankingnews.com - June 16 at 3:30 PM
americanbankingnews.com logoZacks: Analysts Expect NeoGenomics, Inc. (NEO) Will Post Earnings of $0.02 Per Share
www.americanbankingnews.com - June 14 at 2:04 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 13 at 10:51 PM
finance.yahoo.com logoETFs with exposure to NeoGenomics, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 7:41 PM
americanbankingnews.com logoSteven A. Ross Sells 70,833 Shares of NeoGenomics, Inc. (NEO) Stock
www.americanbankingnews.com - June 6 at 7:50 PM
finance.yahoo.com logoNeoGenomics, Inc. :NEO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 7:29 PM
finance.yahoo.com logoNeoGenomics, Inc. breached its 50 day moving average in a Bullish Manner : NEO-US : June 5, 2017
finance.yahoo.com - June 5 at 8:59 AM
finance.yahoo.com logoNeoGenomics Announces Expansion of Immuno-Oncology Profiling Tests
finance.yahoo.com - June 2 at 8:09 PM
streetinsider.com logoForm 4 NEOGENOMICS INC For: May 25 Filed by: TETRAULT LYNN A.
www.streetinsider.com - May 31 at 9:46 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) VP Sells $25,005.00 in Stock
www.americanbankingnews.com - May 30 at 8:31 PM
americanbankingnews.com logoBTIG Research Reiterates "Buy" Rating for NeoGenomics, Inc. (NEO)
www.americanbankingnews.com - May 28 at 7:20 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Given a $11.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 27 at 9:34 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 19 at 11:06 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Expected to Announce Earnings of $0.02 Per Share
www.americanbankingnews.com - May 17 at 4:16 PM
finance.yahoo.com logoNeoGenomics Reports that its NeoLAB(R) Liquid Biopsy Prostate Test is More Accurate than Conventional Biopsies in Predicting High Grade Prostate Cancer
finance.yahoo.com - May 15 at 10:13 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:14 AM
americanbankingnews.com logoNeoGenomics (NEO) Getting Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - May 4 at 1:21 AM
americanbankingnews.com logoNeoGenomics (NEO) Receiving Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 30 at 3:27 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 28 at 8:00 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Expected to Post Quarterly Sales of $65.99 Million
www.americanbankingnews.com - April 28 at 1:16 PM

Social

Chart

NeoGenomics (NEO) Chart for Saturday, August, 19, 2017

This page was last updated on 8/19/2017 by MarketBeat.com Staff